Study on Structum® in Adult Patients With Osteoarthritis (TRUST)

CompletedOBSERVATIONAL
Enrollment

151

Participants

Timeline

Start Date

June 27, 2023

Primary Completion Date

October 28, 2024

Study Completion Date

October 28, 2024

Conditions
Osteoarthritis, Knee
Interventions
DRUG

Chondroitin sulfate

Chondroitin sulfate (CS) is a natural biomacromolecule belonging to the class of glycosaminoglycans and is an unbranched complex polysaccharide consisting of a repeating disaccharide structure of glucuronic acid and N-acetyl-D-glucosamine \[18\]. It is a major component of the extracellular matrix (ECM), where it constitutes an essential component of proteoglycans. Oral bioavailability of CS has been demonstrated \[19\], and its use for the treatment of OA has been established in animal models \[20\], as well as in clinical trials \[21, 22\]. CS, is available as a pharmaceutical grade drug (Structum®), meaning that the product is manufactured under Good Manufacturing Practices (GMP) conditions, and is in excess of 99% purity with no binders, fillers, excipients, dyes, or unknown substances. According to the Instructions for Use (IFU), the recommended posology for Structum® is 500 mg twice daily.

Trial Locations (15)

15-481

Maciej Dołżyński, Bialystok

85-091

Piotr Ligocki, Bydgoszcz

40-007

Elżbieta Pietrus- Dunaszewska, Katowice

31-155

Bartlomiej Szpyra, Krakow

31-455

Alina Wołkowicz Mruk, Krakow

46-211

Andrzej Majer, Kujakowice Gorn

21-100

Agnieska WIAK, Lubartów

82-100

Wojciech Larczyński, Nowy Dwór Gdański

46-300

Sławomir Panek, Olesno

71-497

Marcin Milchert, Szczecin

Ustrzyki Dolne

Wojciech Roczniak, Ustrzyki Dolne

03-938

Zdzisław Derleta, Warsaw

65-047

Michał Straburzyński, Zielona Góra

65-559

Mariusz Borowiecki, Zielona Góra

68-100

Viktor Kostiuk, Żagań

All Listed Sponsors
lead

Pierre Fabre Medicament

INDUSTRY